Initial Results of a Phase 2 Trial of
| Autor: | Nadia Nicole, Laack, Deanna, Pafundi, S Keith, Anderson, Timothy, Kaufmann, Val, Lowe, Christopher, Hunt, Diane, Vogen, Elizabeth, Yan, Jann, Sarkaria, Paul, Brown, Sani, Kizilbash, Joon, Uhm, Michael, Ruff, Mark, Zakhary, Yan, Zhang, Maasa, Seaberg, Hok Seum, Wan Chan Tseung, Brian, Kabat, Bradley, Kemp, Debra, Brinkmann |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Kaplan-Meier Estimate Methylation O(6)-Methylguanine-DNA Methyltransferase Young Adult Antineoplastic Agents Immunological Cognition Confidence Intervals Temozolomide Humans Prospective Studies Antineoplastic Agents Alkylating Aged Aged 80 and over Brain Neoplasms Middle Aged Progression-Free Survival Dihydroxyphenylalanine Bevacizumab Chemotherapy Adjuvant Positron-Emission Tomography Quality of Life Female Dose Fractionation Radiation Radiopharmaceuticals Glioblastoma Radiotherapy Image-Guided |
| Zdroj: | International journal of radiation oncology, biology, physics. 110(5) |
| ISSN: | 1879-355X |
| Popis: | Our previous work demonstrated that 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (Patients with newly diagnosed, histologically confirmed glioblastoma aged ≥18 years without contraindications toBetween January 2014 and December 2018, 75 evaluable patients were enrolled (39 DE-Un, 24 methylated [DE-Mth], and 12 indeterminate). PFS6 for DE-Un was 79.5% (95% confidence interval, 63.1%-90.1%). Median PFS was longer for DE-Un patients compared with historical controls (8.7 months vs 6.6 months; P = .017). OS was similarly longer, but the difference was not significant (16.0 vs 13.5 months; P = .13). OS was significantly improved for DE-Mth patients compared with HC-Mth (35.5 vs 23.3 months; P = .049) despite nonsignificant improvement in PFS (10.7 vs 9.0 months; P = .26). Grade 3 central nervous system necrosis occurred in 13% of patients, but treatment with bevacizumab improved symptoms in all cases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|